An acetic acid derivative ketorolac tromethmine has found its applicability in both gram positive and gram negative bacterial ocular infection and used commonly associated with multiple doses. Ophthalmic medication stored in multiple dose containers is required by the U.S. Food and Drug Administration to contain a preservative so that patients are provided with microbe free medication. Benzalkonium chloride in concentrations from 0.1% to 0.0001% induced dose-dependent growth arrest and conjunctiva epithelial cell death, either delayed or immediately after administration. In such case, a preservative Benzalkonium chloride must be used within reasonable bound. Benzalkonium chloride can provide more help than harm. Hence the present study focusing on to formulate a formulation for ketorolac tromethmine (0.5%) ophthalmic solution using different concentration of Benzalkonium chloride as preservative.
INTRODUCTION
Delivery of medication to the human eye is an integral part of medical treatment. Ophthalmic drug delivery is one of the most interesting and challenging endeavours facing the pharmaceutical scientist. The anatomy, physiology, and biochemistry of the eye render this organ highly impervious to foreign substances 1 . A significant challenge to the formulator is to circumvent the protective barriers of the eye without causing permanent tissue damage. Development of newer, more sensitive diagnostic techniques and novel therapeutic agents continue to provide ocular delivery systems with high therapeutic efficacy 2 . Ophthalmic preparations are specialized dosage forms designed to be instilled onto the external surface of eye (topical), administered inside (intraocular), adjacent to the eye (periocular) or used in conjunction with any special device. The preparation may have any several purposes like therapeutic, prophylactic or palliative 3, 4 . The versatility of dosage form enables therapeutic agent to be suitable for function of preparation. Therapeutically active formulation may be designed to provide extended action for either convenience or reduction in dose frequency, improved bioavailability of an agent or improved delivery to target tissue. The residence time of an ocular preparation may range from few seconds (ophthalmic solutions) to hours (gel, ointments), to months or years (intra ocular or periocular dosage forms). Ophthalmic preparations are similar to parenteral dosage form in their requirements for sterility as well as consideration for osmotic pressure (tonicity), preservation, and tissue compatibility, avoidance of pyrogen and particulate matter and suitable packaging 5, 6, 7 .
This effect of NSAIDs is due to the inhibition of the enzyme COX, which converts arachidonic acid to prostaglandins, TXA2 and prostacyclin. 
Analgesic effect of NSAIDs
This effect of NSAIDs is thought to be related to the peripheral inhibition of prostaglandin production, but it may also be due to the inhibition of pain stimuli at a subcortical site.
NDAIDs prevent the potentiating action of prostaglandins on endogenous mediators of peripheral nerve stimulation (e.g. bradykinin)
Ketorolac tromethamine is a nonsteroidal antiinflammatory drug which, when administered systemically, has demonstrated analgesic, antiinflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis. Ketorolac tromethamine given systemically does not cause pupil constriction 11 .
Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humour barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure 12, 13 . Prostaglandins also appear to play a role in the mitotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms 14, 15 .
MATERIAL AND METHODS
Ketorolac tromethamine was received as generous gift from MSN Laboratories Ltd, Medak, A.P India. Benzalkonium chloride USP, Sodium chloride USP, Disodium EDTA USP, Sodium hydroxide USP, Hydrochloric acid USP, were received from Merck Chemicals Mumbai. All other chemicals used were of analytical reagent grade, available commercially and used as such without further processing.
Methods:
The excipients Benzalkonium chloride is used as preservative, sodium chloride as isotonic modifier and remaining are as diluents.
Collect of water for injection in a cleaned glass container and parching it with nitrogen gas for 30 min. Take some of water for injection of in cleaned stainless steel vessels to it add and dissolve EDTA disodum, octoxynol40, sodium chloride under continuous stirring to get a clear solution. Weigh accurate batch quantity of Ketorolac tromethamine add and dissolve it into the bulk solution of under constant stirring to dissolve it completely. Measure accurate quantity of benzalkonium chloride and add and dissolve it into the bulk solution of step no3 to dissolve it completely. Check the pH of the resultant bulk solution and if necessary, adjust the pH to 7.4 using 1N Sodium Hydroxide solution for 1N Hydrochloric acid solution. Make up the volume of the bulk solution to 1 litre using water for injection.
Remove the resultant solution (approx) as a before filtration sample and submit it for analysis. Filter the remaining bulk solution through 0.22 µ PVDF membrane filter submit the after filtration sample for analysis. Fill the filtered bulk solution into 5ml 3 piece and 5ml BFS containers with fill volume of 3ml The A criteria express the recommended efficacy to be achieved. In justified case where the A criteria cannot be attained, for example for reasons of an increased risk of adverse reactions, the B criteria must be satisfied. Report the results in the Summary Report.
RESULT & DISCUSSION

Stability
The design of the formal stability studies for the drug product should be based on knowledge of the behavior and properties of drug substance and from stability studies on the drug substances. The likely changes on storage and the rationale attributes to be tested in formal stability studies should be stated. From the above stability report for six months at different temperature and humidity condition the product is found to be stable and complies according to the limit.
CONCLUSION
The designed optimized formulation T-6 with minimum concentration of Benzalkonium chloride will provide better therapeutic effect without the corneal irritation caused due the deposition of Benzalkonium chloride. The optimized formulation with minimum concentration of Benzalkonium chloride, will meet the compendia requirement of preservative efficacy test, so that it will maintain the sterility of the product throughout the shelf life of product. Formulation has effective antimicrobial activity without interference with the mechanism of action of the active ingredient. As there will no eye irritation and conjunctival epithelial cell death, optimized formulation will help to achieve the better patient compliance and improved therapeutics with reduced systemic side effects and toxicity in ocular bacterial infection. The selected packaging material will provide the better stability at both room and elevated conditions of temperature and humidity. No or minimum introduction of extractable and leachable in the product from the packaging material.
